Minervasäätiö

Minervasäätiö

Founded in 1959 by physicians Bertel von Bonsdorff, Bror-Axel Lamberg, Wolmar Nyberg, and Ralph Gräsbeck, Minervasäätiö (the Minerva Foundation) began as a rented laboratory at Helsinki’s Konkordia Hospital. The founders were senior researchers at the University of Helsinki’s Fourth Department of Medicine who lacked physical space. Their early work produced foundational findings — including isolation of Castle’s intrinsic factor and the discovery of haptocorrin — and the foundation’s Institute went on to train scientists such as geneticist Albert de la Chapelle and cell biologist Kai Simons. The foundation’s balance sheet took an unusual path. Because Finnish law barred charitable foundations from conducting commercial work, the scientists founded a for-profit laboratory company, Medix Ltd., in the 1970s, donating their shares to Minervasäätiö, Folkhälsan, and the Liv och Hälsa Society with a covenant that all profit fund research. The resulting enterprise grew into Yhtyneet Medix Laboratoriot, Finland’s largest private reference laboratory, and Medix Biochemica, a monoclonal-antibody producer exporting globally. In 2016 the foundation sold a majority stake in the Medix group and redeployed proceeds into a diversified securities and stock-market portfolio. The foundation’s real assets include ownership stakes in Kiinteistö Oy Biomedicum Helsinki, the commercial property housing its research institute. Financial governance sits with a committee chaired by M.Sc. Kim Karhu, while the Board of Trustees is led by Professor Patrik Finne. An agent, Patrik Lerche, handles day-to-day operations from the Jätkäsaarenkuja office. The foundation is a member of Säätiöt ja rahastot, the Association of Finnish Foundations. Research funding flows through annual grants and named prizes — including the Bror Axel Lamberg Prize, awarded to Professor Outi Mäkitie in 2025 — and the Minerva Institute operates in close collaboration with the University of Helsinki and HUS Helsinki University Hospital, its co-shareholders in the Biomedicum complex. The structural differentiator is Minervasäätiö’s origin as a scientist-created endowment that financed itself for decades via a wholly-owned diagnostics business before liquidating it into a liquid portfolio. That sequence — from pooled academic grants to controlling a national reference laboratory to a publicly unnamed securities allocation — has no close parallel among Nordic medical foundations. The biomedical mission remained walled off from commercial exigency even when the foundation was Medix’s controlling shareholder, a governance separation that persisted through the 2016 exit and into the current grantmaking cycle.